SOURCE: Implant Sciences

Implant Sciences

April 27, 2011 15:41 ET

Implant Sciences CEO to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 29

WILMINGTON, MA--(Marketwire - Apr 27, 2011) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that its CEO, Glenn Bolduc, will present at the Aegis Capital Emerging Growth Conference on Friday, April 29th from 12:00 to 12:45pm. The conference will take place between April 28 and April 30 at the Palazzo Hotel in Las Vegas.

Mr. Bolduc will discuss Implant Sciences' growth strategy as it continues to experience increased revenues driven by sales of its explosives trace detection equipment through its global distribution network.

Aegis Capital is a full-service retail and institutional broker-dealer with investment banking that specializes in financial services to companies with high growth potential.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact
    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact